NeoGenomics — Third Quarter 2026 Earnings Summary

Financial Performance

• Preliminary unaudited third quarter total revenue is expected to be approximately $209 million.
• Third quarter next-generation sequencing (NGS) revenue is expected to grow approximately 28% year-over-year.
• Full year total revenue guidance is expected to increase at the midpoint resulting from third quarter performance.
• Full year adjusted EBITDA guidance is reiterated as provided on July 28, 2026.
• Preliminary results are unaudited and subject to completion of quarter-end closing procedures and potential final adjustments.

Guidance and Future Outlook

• The Company expects to provide further details regarding the expected increase to full-year total revenue guidance on the third quarter earnings call.
• Management expects to deliver durable, profitable growth consistent with its aligned long-term strategy.

Business Segments and Product Lines

• NGS revenue growth is highlighted as a key performance driver within the oncology diagnostics sector.
• Strategic priorities include commercial expansion, customer impact, new product introductions, and "Lab of the Future" initiatives.

Management Commentary and Tone

• CEO Tony Zook stated the leadership transition reflects years of deliberate succession planning and cements continuity of the executive team and strategy.
• Zook noted Warren Stone's ability to lead enterprise-wide functions and advance key priorities over the past several years.
• Incoming CEO Warren Stone expressed that the mission is ensuring every treatment decision is personal and stated the company is exceptionally well-positioned to lead the evolution of the oncology diagnostics market.
• Outgoing Chair Lynn Tetrault expressed pride in the organization's achievements and stated the Board is committed to positioning NeoGenomics for long-term success.

Risks and Challenges

• Risks include the ability to successfully complete executive leadership and Board transitions without business disruption.
• Potential challenges involve assembling and maintaining an effective executive team and retaining key personnel during and following the transition.
• Risks include the effectiveness of the new Board leadership structure and the ability to achieve preliminary financial expectations.
• External risks include evolving regulatory requirements related to laboratory developed tests, tariffs and trade policy uncertainty affecting supply chains and costs, and potential reimbursement changes by government and commercial payors.

Other Key Points

• Warren Stone, current President and COO, will become CEO and a Board member effective January 4, 2027.
• Tony Zook will remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027.
• Lynn Tetrault will step down as Chair effective January 4, 2027, continue as an independent director until the 2027 Annual Meeting of Stockholders, and will not stand for reelection.
• Michael Kelly, an independent Board member since 2020, will serve as Lead Independent Director effective January 4, 2027.
• Warren Stone has over three decades of Life Sciences and Diagnostics leadership experience, including senior roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA, and joined NeoGenomics in 2022.